RaQualia Pharma Inc. - Laporan Laba Rugi (TTM)

RaQualia Pharma Inc.
JP ˙ TSE ˙ JP3967150008
JP¥ 576.00 ↑14.00 (2.49%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi RaQualia Pharma Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,567 1,107 1,639 2,055 2,157 2,776 2,460 2,903 3,057 2,918 2,949 2,485 2,509 1,901 2,179 2,298 2,775 3,107 3,424 3,231
Change (%) -29.36 48.06 25.38 4.96 28.70 -11.38 18.01 5.30 -4.55 1.06 -15.73 0.97 -24.23 14.62 5.46 20.76 11.96 10.22 -5.65
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 193 138 154 255 309 321 334 250 221 231 237 249 252 245 246 350 452 625 788 787
Change (%) -28.50 11.59 65.58 21.18 3.88 4.05 -25.15 -11.60 4.52 2.60 5.06 1.20 -2.78 0.41 42.28 29.28 38.13 26.01 -0.07
% of Revenue 12.32 12.47 9.40 12.41 14.33 11.56 13.58 8.61 7.23 7.92 8.04 10.02 10.04 12.89 11.29 15.23 16.30 20.12 23.00 24.36
Gross Operating Profit 1,374 969 1,485 1,800 1,848 2,455 2,126 2,653 2,836 2,687 2,712 2,236 2,257 1,656 1,933 1,948 2,323 2,482 2,637 2,444
Change (%) -29.48 53.25 21.21 2.67 32.85 -13.40 24.79 6.90 -5.25 0.93 -17.55 0.94 -26.63 16.73 0.78 19.23 6.86 6.24 -7.31
% of Revenue 87.68 87.53 90.60 87.59 85.67 88.44 86.42 91.39 92.77 92.08 91.96 89.98 89.96 87.11 88.71 84.77 83.70 79.88 77.00 75.64
SG&A 552 518 580 584 583 615 547 544 543 566 575 615 651 615 648 809 886 782 1,072 831
Change (%) -6.16 11.97 0.69 -0.17 5.49 -11.06 -0.55 -0.18 4.24 1.59 6.96 5.85 -5.53 5.37 24.85 9.50 -11.72 37.03 -22.45
% of Revenue 35.23 46.79 35.39 28.42 27.03 22.15 22.24 18.74 17.76 19.40 19.50 24.75 25.95 32.35 29.74 35.20 31.92 25.17 31.29 25.72
R&D 901 932 964 978 1,037 1,127 1,135 1,159 1,187 1,248 1,253 1,323 1,342 1,372 1,463 1,601 1,693 1,703 1,730 1,653
Change (%) 3.44 3.43 1.45 6.03 8.68 0.71 2.11 2.42 5.14 0.40 5.59 1.44 2.24 6.63 9.43 5.77 0.57 1.59 -4.45
% of Revenue 57.50 84.19 58.82 47.59 48.08 40.60 46.14 39.92 38.83 42.77 42.49 53.24 53.49 72.17 67.14 69.67 61.02 54.81 50.52 51.16
OpEx 1,650 1,593 1,703 1,822 1,934 2,068 2,021 1,958 1,956 2,051 2,071 2,193 2,251 2,238 2,363 2,766 3,032 3,320 3,589 3,481
Change (%) -3.45 6.91 6.99 6.15 6.93 -2.27 -3.12 -0.10 4.86 0.98 5.89 2.64 -0.58 5.59 17.05 9.60 9.51 8.11 -3.01
% of Revenue 105.30 143.90 103.90 88.66 89.66 74.50 82.15 67.45 63.98 70.29 70.23 88.25 89.72 117.73 108.44 120.37 109.24 106.86 104.81 107.74
Operating Income -83 -486 -64 233 223 708 439 945 1,101 867 878 292 258 -337 -184 -468 -257 -213 -165 -250
Change (%) 485.54 -86.83 -464.06 -4.29 217.49 -37.99 115.26 16.51 -21.25 1.27 -66.74 -11.64 -230.62 -45.40 154.35 -45.19 -16.96 -22.63 51.71
% of Revenue -5.30 -43.90 -3.90 11.34 10.34 25.50 17.85 32.55 36.02 29.71 29.77 11.75 10.28 -17.73 -8.44 -20.37 -9.24 -6.86 -4.81 -7.74
Interest Expense -1 -1 -3 -5 -6 -8 -7 -7 -7 -7 -20 -31 -42 -55 -56
Change (%) -0.00 200.00 66.67 20.00 33.33 -12.50 -0.00 -0.00 -0.00 185.71 55.82 34.77 31.30 1.55
% of Revenue -0.04 -0.04 -0.10 -0.16 -0.21 -0.27 -0.28 -0.28 -0.37 -0.32 -0.87 -1.12 -1.35 -1.61 -1.73
Net Income -162 -606 -90 155 261 755 447 922 1,053 723 695 279 139 -323 -253 -671 -546 -495 -422 -526
Change (%) 274.07 -85.15 -272.22 68.39 189.27 -40.79 106.26 14.21 -31.34 -3.87 -59.86 -50.18 -332.37 -21.67 165.22 -18.64 -9.33 -14.72 24.60
% of Revenue -10.34 -54.74 -5.49 7.54 12.10 27.20 18.17 31.76 34.45 24.78 23.57 11.23 5.54 -16.99 -11.61 -29.20 -19.67 -15.93 -12.33 -16.28

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista